Shareef M. Syed

Shareef M. Syed

Auto-generated profile, based on publicly available information

Shareef M. Syed

Department of Surgery, University of California, San Francisco, San Francisco, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 January 2025 in Nature Biotechnology
Verified
Journal Article
Open access
PDF file
JKJae-Jun Kim
Jae-Jun Kim
SKSimone N. T. Kurial
Simone N. T. Kurial
PCPervinder K. Choksi
Pervinder K. Choksi
MNMiguel Nunez
Miguel Nunez
TLTyler Lunow-Luke
Tyler Lunow-Luke
HWHolger Willenbring
Holger Willenbring
Therapeutic efficacy and safety of adeno-associated virus (AAV) liver gene therapy depend on capsid choice. To predict AAV capsid performance under near-clinical conditions, we established side-by-side comparison at single-cell resolution in human livers maintained by normothermic machine perfusion. AAV-LK03 transduced hepatocytes much more efficiently and specifically than AAV5, AAV8 and AAV6, which are most commonly used clinically, and AAV-NP59, which is better at transducing human hepatocytes engrafted in immune-deficient mice. AAV-LK03 preferentially transduced periportal hepatocytes in normal liver, whereas AAV5 targeted pericentral hepatocytes in steatotic liver. AAV5 and AAV8 transduced liver sinusoidal endothelial cells as efficiently as hepatocytes. AAV capsid and steatosis influenced vector episome formation, which determines gene therapy durability, with AAV5 delaying concatemerization. Our findings inform capsid choice in clinical AAV liver gene therapy, including consideration of disease-relevant hepatocyte zonation and effects of steatosis, and facilitate the development of AAV capsids that transduce hepatocytes or other therapeutically relevant cell types in the human liver with maximum efficiency and specificity.

1 January 2022 in American Journal of Transplantation
Verified
Journal Article
Open access
VCValerie Chipman
Valerie Chipman
MCMatthew Cooper
Matthew Cooper
ATAlvin G. Thomas
Alvin G. Thomas
MRMatthew Ronin
Matthew Ronin
BLBrian Lee
Brian Lee
GRGarrett R. Roll
Garrett R. Roll
Increasing numbers of compatible pairs are choosing to enter paired exchange programs, but motivations, outcomes, and system-level effects of participation are not well described. Using a linkage of the Scientific Registry of Transplant Recipients and National Kidney Registry, we compared outcomes of traditional (originally incompatible) recipients to originally compatible recipients using the Kaplan–Meier method. We identified 154 compatible pairs. Most pairs sought to improve HLA matching. Compared to the original donor, actual donors were younger (39 vs. 50 years, p < .001), less often female (52% vs. 68%, p < .01), higher BMI (27 vs. 25 kg/m2, p = .03), less frequently blood type O (36% vs. 80%, p < .001), and had higher eGFR (99 vs. 94 ml/min/1.73 m2, p = .02), with a better LKDPI (median 7 vs. 22, p < .001). We observed no differences in graft failure or mortality. Compatible pairs made 280 additional transplants possible, many in highly sensitized recipients with long wait times. Compatible pair recipients derived several benefits from paired exchange, including better donor quality. Living donor pairs should receive counseling regarding all options available, including kidney paired donation. As more compatible pairs choose to enter exchange programs, consideration should be given to optimizing compatible pair and hard-to-transplant recipient outcomes.

23 February 2024 in Current Anesthesiology Reports
Verified
Journal Article
Open access
PDF file
SMSivan G. Marcus
Sivan G. Marcus
SSShareef Syed
Shareef Syed
AAAlexandra L. Anderson
Alexandra L. Anderson
MBMichael P. Bokoch
Michael P. Bokoch
Purpose of Review: This review summarizes the updated literature on goal-directed therapy during liver surgery. It provides guidance for clinicians regarding physiologic concepts and clinical evidence related to fluid and hemodynamic management strategies during and after liver resection. Recent Findings: Open liver resection presents unique anatomic and physiologic challenges for the anesthesiologist. Care must be taken to reduce hemorrhage via control of inflow and outflow of hepatic blood. Resuscitation should be individualized to the patient and primarily utilize balanced crystalloids, blood products, and possibly albumin. Administration of intravenous fluids should be guided by hemodynamic parameters. Minimally invasive liver resection may be beneficial to patients but presents additional considerations for goal-directed therapy. Summary: Goal-directed therapy can be utilized to decrease blood loss and optimize the surgical field during liver resection. This strategy holds promise to improve patient outcomes after liver surgery.

29 June 2020 in Transplantation
Verified
Journal Article
Closed access
SSShareef M. Syed
Shareef M. Syed
JGJames Gardner
James Gardner
GRGarrett Roll
Garrett Roll
AWAllison Webber
Allison Webber
NMNeil Mehta
Neil Mehta
CFChris Freise
Chris Freise
Background.: The novel severe acute respiratory syndrome coronavirus (SARS-CoV-2) disease has transformed innumerable aspects of medical practice, particularly in the field of transplantation. Main Body.: Here we describe a single-center approach to creating a generalizable, comprehensive, and graduated set of recommendations to respond in stepwise fashion to the challenges posed by these conditions, and the underlying principles guiding such decisions. Conclusions.: Creation of a stepwise plan will allow transplant centers to respond in a dynamic fashion to the ongoing challenges posed by the COVID-19 pandemic.

4 December 2020 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
SWSteven A Wisel
Steven A Wisel
CTCarrie Thiessen
Carrie Thiessen
RDRyan Day
Ryan Day
LBL. Justin Belin
L. Justin Belin
SSShareef M. Syed
Shareef M. Syed
CFChristopher E. Freise
Christopher E. Freise
Croome and Daneshmand offer a thoughtful piece on the complexities of joint DCD heart and liver procurements. The authors have provided important suggestions which, with greater experience, can be expanded and systematized to establish clear, standardized protocols.

28 January 2020 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
GRGarrett R. Roll
Garrett R. Roll
APAndrew M. Posselt
Andrew M. Posselt
JFJonathan Freise
Jonathan Freise
JBJulia Baird
Julia Baird
SSShareef Syed
Shareef Syed
PSPeter G. Stock
Peter G. Stock
The approach to transplantation in human immunodeficiency virus (HIV)‐positive patients has been conservative due to fear of exacerbating an immunocompromised condition. As a result, HIV‐positive patients with diabetes were initially excluded from beta cell replacement therapy. Early reports of pancreas transplant in patients with HIV described high rates of early graft loss with limited follow‐up. We report long‐term follow‐up of islet or pancreas transplantation in HIV‐positive type 1 diabetic patients who received a kidney transplant concurrently or had previously undergone kidney transplantation. Although 4 patients developed polyoma viremia, highly active antiretroviral therapy and adequate infectious prophylaxis were successful in providing protection until CD4+ counts recovered. Coordination with HIV providers is critical to reduce the risk of rejection by minimizing drug‐drug interactions. Also, protocols for prophylaxis of opportunistic infections and strategies for monitoring and treating BK viremia are important given the degree of immunosuppression required. This series demonstrates that type 1 diabetic patients with well‐controlled HIV and renal failure can be appropriate candidates for beta cell replacement, with a low rate of infectious complications, early graft loss, and rejection, so excellent long‐term graft survival is possible. Additionally, patients with HIV and cardiovascular contraindications can undergo islet infusion.